ADVA
11.3.2021 09:02:06 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-P substation grandmaster, an ultra-compact synchronization solution specifically designed for the digital transformation of power utility networks. The OSA 5405-P delivers the precise and reliable timing that utilities need to leverage new smart grid applications, including intelligent power generation, distribution and control systems. The solution protects mission-critical infrastructure from the risk of outages caused by loss of timing from satellite signals by combining GNSS receivers with accurate PTP grandmaster clocks and network-delivered timing. Available with rack, DIN rail and wall mounting options, the OSA 5405-P also reduces cost and complexity in synchronization networks. What’s more, by supporting both legacy and new timing technologies, the solution empowers utility networks to smoothly and cost-effectively transition to next-generation synchronization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005049/en/
“The utility network landscape is changing. With the move to distributed power generation and the digital transformation of substations, utilities face a new set of challenges and opportunities. To succeed, all processes must be tightly synchronized and a new level of accurate, robust timing is required. Our OSA 5405-P addresses these exact needs and offers power network operators a simple and affordable route from legacy synchronization to fully protected and assured PTP timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Now utility networks can leverage a solution tailored to their precise needs that’s easy to install anywhere. And with our sophisticated Ensemble Controller and Sync Director, synchronization is easy to manage and operate.”
The OSA 5405-P offers power network operators a risk-free way to migrate their existing timing infrastructure to the accurate and robust PTP timing needed for new automated technologies and smart grid applications. With network-based synchronization backing up timing from GNSS, the OSA 5405-P removes vulnerability to loss of satellite signals. It supports multiple PTP profiles, including the Power Profile, and features NTP as well as IRIG-B interfaces for precise time synchronization of all power system devices. Its Syncjack™ capabilities also deliver accurate, real-time monitoring of synchronization quality. The OSA 5405-P is the ultimate power utility synchronization solution where cost-efficiency and small footprint are key. With rack and DIN rail mounting options, it’s extremely versatile to deploy. Ideal for secondary substations, it can also complement the OSA 5422-IRIG solution in primary substations. The OSA 5405-P also utilizes in-service sync probing and assurance as well as innovative GNSS assurance capabilities.
“Smart grids need intelligent timing. That’s what our OSA 5405-P offers. It brings assured and protected synchronization to the edge of the power network in an extremely cost-efficient way. Now operators can rely on their infrastructure delivering the robust and accurate timing needed for new secondary substation and protection relay technologies,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “The compact and environmentally friendly design of our solution will be especially valuable as utility networks migrate to packet-based timing. The OSA 5405-P distributes accurate timing with the smallest size and power footprint on the market. That means major savings on rack space and a significant reduction in complexity.”
Further details on the OSA 5405-P are available in these slides: https://adva.li/osa-5405-p-slides .
A supporting solution brief can be downloaded here: https://adva.li/osa-5405-p-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005049/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
